Funding the next generation of lung cancer luminaries.
Biagio Ricciuti, MD
Staff Scientist II - MD at Dana-Farber Cancer Institute
With the support of the ILCF, we have demonstrated that genomically defined subset of lung cancers
harboring mutations in genes involved in DNA damage repair (DDR) derive improved clinical outcomes
with PD-(L)1 blockade.
People who are diagnosed with lung cancer gain hope through improved treatment options resulting from scientific advances. The International Lung Cancer Foundation exists to fund innovative research that leads to scientific advances in the detection and treatment of lung cancer and other thoracic malignancies. We need your help to fund our next round of researchers and their innovative projects. Despite being the leading cause of cancer death, lung cancer receives far less government research funding than any other cancer, so research support from corporations, foundations, and individual donors is crucial.